Skeletal muscle wasting and atrophy is one of the more severe clinical impairments resulting from the progression of Huntington's disease (HD). Mitochondrial dysfunction may play a significant role in the etiology of HD, but the specific condition of mitochondria in muscle has not been widely studied during the development of HD. To determine the role of mitochondria in skeletal muscle during the early stages of HD, we analyzed quadriceps femoris muscle from 24-, 36-, 48- and 66-month-old transgenic minipigs that expressed the N-terminal portion of mutated human huntingtin protein (TgHD) and age-matched wild-type (WT) siblings. We found altered ultrastructure of TgHD muscle tissue and mitochondria. There was also significant reduction of activity of citrate synthase and respiratory chain complexes (RCCs) I, II and IV, decreased quantity of oligomycin-sensitivity conferring protein (OSCP) and the E2 subunit of pyruvate dehydrogenase (PDHE2), and differential expression of optic atrophy 1 protein (OPA1) and dynamin-related protein 1 (DRP1) in the skeletal muscle of TgHD minipigs. Statistical analysis identified several parameters that were dependent only on HD status and could therefore be used as potential biomarkers of disease progression. In particular, the reduction of biomarker RCCII subunit SDH30 quantity suggests that similar pathogenic mechanisms underlie disease progression in TgHD minipigs and HD patients. The perturbed biochemical phenotype was detectable in TgHD minipigs prior to the development of ultrastructural changes and locomotor impairment, which become evident at the age of 48 months. Mitochondrial disturbances may contribute to energetic depression in skeletal muscle in HD, which is in concordance with the mobility problems observed in this model.This article has an associated First Person interview with the first author of the paper.

Department of Medical Biochemistry University of Oslo and Oslo University Hospital 0372 Oslo Norway

Laboratory for Study of Mitochondrial Disorders Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague 12108 Prague 2 Czech Republic

Laboratory of Cell Regeneration and Cell Plasticity Institute of Animal Physiology and Genetics AS CR 27721 Liběchov Czech Republic

Zobrazit více v PubMed

Antoniel M., Giorgio V., Fogolari F., Glick G. D., Bernardi P. and Lippe G. (2014). The oligomycin-sensitivity conferring protein of mitochondrial ATP synthase: emerging new roles in mitochondrial pathophysiology. PubMed DOI PMC

Arenas J., Campos Y., Ribacoba R., Martín M. A., Rubio J. C., Ablanedo P. and Cabello A. (1998). Complex I defect in muscle from patients with Huntington's disease. PubMed DOI

Askeland G., Dosoudilova Z., Rodinova M., Klempir J., Liskova I., Kuśnierczyk A., Bjørås M., Nesse G., Klungland A., Hansikova H. et al. (2018a). Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington's disease patients. PubMed DOI PMC

Askeland G., Rodinova M., Štufková H., Dosoudilova Z., Baxa M., Smatlikova P., Bohuslavova B., Klempir J., Nguyen T. D., Kuśnierczyk A. et al. (2018b). A transgenic minipig model of Huntington's disease shows early signs of behavioral and molecular pathologies. PubMed DOI PMC

Baldwin K. M., Hooker A. M. and Herrick R. E. (1978). Lactate oxidative capacity in different types of muscle. PubMed DOI

Banoei M. M., Houshmand M., Panahi M. S. S., Shariati P., Rostami M., Manshadi M. D. and Majidizadeh T. (2007). Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?! PubMed DOI PMC

Baxa M., Hruska-Plochan M., Juhas S., Vodicka P., Pavlok A., Juhasova J., Miyanohara A., Nejime T., Klima J., Macakova M. et al. (2013). A transgenic minipig model of Huntington's Disease. PubMed DOI

Beck S. J., Guo L., Phensy A., Tian J., Wang L., Tandon N., Gauba E., Lu L., Pascual J. M., Kroener S. et al. (2016). Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease. PubMed DOI PMC

Benchoua A., Trioulier Y., Zala D., Gaillard M.-C., Lefort N., Dufour N., Saudou F., Elalouf J.-M., Hirsch E., Hantraye P. et al. (2006). Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. PubMed DOI PMC

Bradford M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. PubMed DOI

Buck E., Zügel M., Schumann U., Merz T., Gumpp A. M., Witting A., Steinacker J. M., Landwehrmeyer G. B., Weydt P., Calzia E. et al. (2017). High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function. PubMed DOI PMC

Busse M. E., Hughes G., Wiles C. M. and Rosser A. E. (2008). Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington's disease. PubMed DOI

Cahova M., Chrastina P., Hansikova H., Drahota Z., Trnovska J., Skop V., Spacilova J., Malinska H., Oliyarnyk O., Papackova Z. et al. (2015). Carnitine supplementation alleviates lipid metabolism derangements and protects against oxidative stress in non-obese hereditary hypertriglyceridemic rats. PubMed DOI

Carroll J. B., Bates G. P., Steffan J., Saft C. and Tabrizi S. J. (2015). Treating the whole body in Huntington's disease. PubMed DOI

Cherubini M. and Ginés S. (2017). Mitochondrial fragmentation in neuronal degeneration: toward an understanding of HD striatal susceptibility. PubMed DOI

Ciammola A., Sassone J., Alberti L., Meola G., Mancinelli E., Russo M. A., Squitieri F. and Silani V. (2006). Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. PubMed DOI

Ciammola A., Sassone J., Sciacco M., Mencacci N. E., Ripolone M., Bizzi C., Colciago C., Moggio M., Parati G., Silani V. et al. (2011). Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington's disease. PubMed DOI PMC

Fornuskova D., Stiburek L., Wenchich L., Vinsova K., Hansikova H. and Zeman J. (2010). Novel insights into the assembly and function of human nuclear-encoded cytochrome c oxidase subunits 4, 5a, 6a, 7a and 7b. PubMed DOI

Gao J., Wang L., Liu J., Xie F., Su B. and Wang X. (2017). Abnormalities of mitochondrial dynamics in neurodegenerative diseases. PubMed DOI PMC

Gizatullina Z. Z., Lindenberg K. S., Harjes P., Chen Y., Kosinski C. M., Landwehrmeyer B. G., Ludolph A. C., Striggow F., Zierz S. and Gellerich F. N. (2006). Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. PubMed DOI

Hering T., Kojer K., Birth N., Hallitsch J., Taanman J.-W. and Orth M. (2017). Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington's disease R6/2 fragment model. PubMed DOI

Horton T. M., Graham B. H., Corral-Debrinski M., Shoffner J. M., Kaufman A. E., Beal M. F. and Wallace D. C. (1995). Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. PubMed DOI

Hu C., Huang Y. and Li L. (2017). Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals. PubMed DOI PMC

Janssen A. J. M., Trijbels F. J., Sengers R. C., Wintjes L. T., Ruitenbeek W., Smeitink J. A., Morava E., van Engelen B. G., van den Heuvel L. P. and Rodenburg R. J. (2006). Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. PubMed DOI

Kosinski C. M., Schlangen C., Gellerich F. N., Gizatullina Z., Deschauer M., Schiefer J., Young A. B., Landwehrmeyer G. B., Toyka K. V., Sellhaus B. et al. (2007). Myopathy as a first symptom of Huntington's disease in a Marathon runner. PubMed DOI

Kremer B., Goldberg P., Andrew S. E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E. et al. (1994). A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. PubMed DOI

Krizova J., Stufkova H., Rodinova M., Macakova M., Bohuslavova B., Vidinska D., Klima J., Ellederova Z., Pavlok A., Howland D. S. et al. (2017). Mitochondrial metabolism in a large-animal model of huntington disease: the hunt for biomarkers in the spermatozoa of presymptomatic minipigs. PubMed DOI

Kuznetsov A. V., Veksler V., Gellerich F. N., Saks V., Margreiter R. and Kunz W. S. (2008). Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. PubMed DOI

Liu C.-S., Cheng W.-L., Kuo S.-J., Li J.-Y., Soong B.-W. and Wei Y.-H. (2008). Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. PubMed DOI

Lodi R., Schapira A. H. V., Manners D., Styles P., Wood N. W., Taylor D. J. and Warner T. T. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. PubMed DOI

Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951). Protein measurement with the Folin phenol reagent. PubMed

Lund J., Aas V., Tingstad R. H., van Hees A. and Nikolić N. (2018). Utilization of lactic acid in human myotubes and interplay with glucose and fatty acid metabolism. PubMed DOI PMC

Macakova M., Bohuslavova B., Vochozkova P., Pavlok A., Sedlackova M., Vidinska D., Vochyanova K., Liskova I., Valekova I., Baxa M. et al. (2016). Mutated Huntingtin causes testicular pathology in transgenic minipig boars. PubMed DOI

Mantovani S., Gordon R., Li R., Christie D. C., Kumar V. and Woodruff T. M. (2016). Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. PubMed DOI

Mielcarek M., Toczek M., Smeets C. J. L. M., Franklin S. A., Bondulich M. K., Jolinon N., Muller T., Ahmed M., Dick J. R. T., Piotrowska I. et al. (2015). HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PubMed DOI PMC

Mosca F., Fattorini D., Bompadre S. and Littarru G. P. (2002). Assay of coenzyme Q(10) in plasma by a single dilution step. PubMed DOI

Munsie L., Caron N., Atwal R. S., Marsden I., Wild E. J., Bamburg J. R., Tabrizi S. J. and Truant R. (2011). Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. PubMed DOI PMC

Novak M. J. U. and Tabrizi S. J. (2010). Huntington's disease. PubMed DOI

Pandey M., Varghese M., Sindhu K. M., Sreetama S., Navneet A. K., Mohanakumar K. P. and Usha R. (2008). Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. PubMed DOI

Panov A. V., Gutekunst C.-A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. and Greenamyre J. T. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. PubMed DOI

Petersen M. H., Budtz-Jørgensen E., Sørensen S. A., Nielsen J. E., Hjermind L. E., Vinther-Jensen T., Nielsen S. M. B. and Nørremølle A. (2014). Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington's disease. PubMed DOI

Quintanilla R. A., Jin Y. N., von Bernhardi R. and Johnson G. V. W. (2013). Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. PubMed DOI PMC

Reddy P. H. (2014). Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. PubMed DOI PMC

Roe A. J. and Qi X. (2018). Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington's disease. PubMed DOI PMC

Romanello V., Guadagnin E., Gomes L., Roder I., Sandri C., Petersen Y., Milan G., Masiero E., DEL Piccolo P., Foretz M. et al. (2010). Mitochondrial fission and remodelling contributes to muscle atrophy. PubMed DOI PMC

Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A. and Rustin P. (1997). Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. PubMed DOI

Rustin P., Chretien D., Bourgeron T., Gérard B., Rötig A., Saudubray J. M. and Munnich A. (1994). Biochemical and molecular investigations in respiratory chain deficiencies. PubMed DOI

Rustin P., Munnich A. and Rötig A. (2002). Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. PubMed DOI

Schägger H. and von Jagow G. (1991). Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. PubMed DOI

She P., Zhang Z., Marchionini D., Diaz W. C., Jetton T. J., Kimball S. R., Vary T. C., Lang C. H. and Lynch C. J. (2011). Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. PubMed DOI PMC

Silva A. C., Almeida S., Laço M., Duarte A. I., Domingues J., Oliveira C. R., Januário C. and Rego A. C. (2013). Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers. PubMed DOI

Squitieri F., Falleni A., Cannella M., Orobello S., Fulceri F., Lenzi P. and Fornai F. (2010). Abnormal morphology of peripheral cell tissues from patients with Huntington disease. PubMed DOI

Srere D. (1969). [1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. DOI

Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G., Cooper J. M. and Schapira A. H. V. (2000). Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. PubMed DOI

Trottier Y., Devys D., Imbert G., Saudou F., An I., Lutz Y., Weber C., Agid Y., Hirsch E. C. and Mandel J.-L. (1995). Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. PubMed DOI

Tyler D. D. (1992).

Valadão P. A. C., de Aragão B. C., Andrade J. N., Magalhães-Gomes M. P. S., Foureaux G., Joviano-Santos J. V., Nogueira J. C., Ribeiro F. M., Tapia J. C. and Guatimosim C. (2017). Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington's disease. PubMed DOI

van der Burg J. M. M., Björkqvist M. and Brundin P. (2009). Beyond the brain: widespread pathology in Huntington's disease. PubMed DOI

Vidinská D., Vochozková P., Šmatlíková P., Ardan T., Klíma J., Juhás S., Juhásová J., Bohuslavová B., Baxa M., Valeková I. et al. (2018). Gradual phenotype development in Huntington disease transgenic minipig model at 24 months of age. PubMed DOI

Vonsattel J. P. G. and Difiglia M. (1998). Huntington disease. PubMed DOI

Wang W., Scheffler K., Esbensen Y. and Eide L. (2016). Quantification of DNA damage by real-time qPCR. PubMed DOI

Zielonka D., Piotrowska I., Marcinkowski J. T. and Mielcarek M. (2014). Skeletal muscle pathology in Huntington's disease. PubMed DOI PMC

Mitochondrial Dysfunction in a High Intraocular Pressure-Induced Retinal Ischemia Minipig Model

Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next

Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration

Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington's disease